Early career researcher receives funding to study how cancer cells communicate with other cells in a tumour, in the hope of finding potential treatment targets.
90% who had low immune response during initial vaccinations developed antibodies, but more than half of non-respondents from first jabs saw no booster benefit
Researchers from The University of Birmingham have created a new £12M research centre to improve clinical trials for rare diseases.
Targeting RAS family proteins in FLT3-ITD+ Acute Myeloid Leukemia shuts off a common route to drug resistance.
Professor Gary Middleton, Professor of Oncology, will be at the forefront of pioneering cancer research as ECMC Network Lead.
New study provides clues to why leukaemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment.
Using urinary DNA to detect circulating tumour DNA in bladder cancer patients
To mark four decades of funding, the Birmingham Cancer Research UK Clinical Trials Unit (CRCTU) held a special celebratory event in January.
Phase 2 trial found adding Bevacizumab to different chemotherapy drugs led to more patients’ tumours shrinking, which has helped to change routine UK treatment.
Screening research found that removal of RUNX1 transcription factor and target gene could lead to network collapse and cancer cell death